Our flagship product, hStroke, harnesses the power of deep learning to assess critical findings on neuroimaging, including traumatic and non-traumatic brain hemorrhage on head CT, large vessel occlusion on head CT angiography, and ischemic stroke on diffusion imaging. Emergency neuro cases are both common and time-sensitive, making rapid and accurate diagnosis crucial for effective treatment and improved patient outcomes. To further enhance accessibility and communication, hStroke features a mobile app that allows doctors to review results and collaborate seamlessly. Additionally, smartwatch integration enables medical professionals to stay informed and connected, even when they're on the move.

Set to deploy in hospitals during the second half of 2023, our hProstate solution streamlines prostate MRI readings for assessing prostate cancer. Utilizing advanced deep learning models, hProstate automatically interprets bi-parametric prostate MRI scans, providing automated prostate volume measurements, PSA density calculations, PI-RADS scores, and detection of clinically significant prostate cancer. With prostate cancer being one of the most common cancers among men, timely and precise MRI interpretations play a critical role in successful treatment and management.

Our third product, hChestXR, is currently under development and slated for release in Q1 2024. This powerful tool can assess the 10 most common pathologies in chest x-ray scans in just minutes, offering radiologists a valuable aid in diagnosing conditions such as pneumonia, pleural effusion, and lung cancer. By streamlining the interpretation process, hChestXR enables healthcare providers to deliver faster, more accurate diagnoses, ultimately improving patient care and outcomes. With the accompanying mobile app, doctors can conveniently access results and communicate with colleagues, while smartwatch integration ensures they remain up-to-date and engaged at all times.